Cargando…
Inflammatory Indexes as Prognostic Factors of Survival in Geriatric Patients with Hepatocellular Carcinoma: A Case Control Study of Eight Slovak Centers
Background and Aims: Hepatocellular cancer (HCC) often occurs in geriatric patients. The aim of our study was to compare overall survival and progression-free survival between geriatric patients (>75 years) and patients younger than 75 years and to identify predictive factors of survival in geria...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9318669/ https://www.ncbi.nlm.nih.gov/pubmed/35887947 http://dx.doi.org/10.3390/jcm11144183 |
_version_ | 1784755350132490240 |
---|---|
author | Safcak, Dominik Drazilova, Sylvia Gazda, Jakub Andrasina, Igor Adamcova-Selcanova, Svetlana Balazova, Lea Barila, Radovan Mego, Michal Rac, Marek Skladany, Lubomir Zigrai, Miroslav Janicko, Martin Jarcuska, Peter |
author_facet | Safcak, Dominik Drazilova, Sylvia Gazda, Jakub Andrasina, Igor Adamcova-Selcanova, Svetlana Balazova, Lea Barila, Radovan Mego, Michal Rac, Marek Skladany, Lubomir Zigrai, Miroslav Janicko, Martin Jarcuska, Peter |
author_sort | Safcak, Dominik |
collection | PubMed |
description | Background and Aims: Hepatocellular cancer (HCC) often occurs in geriatric patients. The aim of our study was to compare overall survival and progression-free survival between geriatric patients (>75 years) and patients younger than 75 years and to identify predictive factors of survival in geriatric patients with HCC. Material and Methods: We performed a retrospective analysis of patients with HCC diagnosed in Slovakia between 2010–2016. Cases (HCC patients ≥75 years) were matched to controls (HCC patients <74 years) based on the propensity score (gender, BCLC stage and the first-line treatment). Results: We included 148 patients (84 men, 57%) with HCC. There were no differences between cases and controls in the baseline characteristics. The overall survival in geriatric patients with HCC was comparable to younger controls (p = 0.42). The one-, two-, and three-year overall survival was 42% and 31%, 19% and 12%, and 12% and 9% in geriatric patients and controls, respectively (p = 0.2, 0.4, 0.8). Similarly, there was no difference in the one- and two-year progression-free survival: 28% and 18% vs. 10% and 7% in geriatric HCC patients and controls, respectively (p = 0.2, 1, -). There was no case–control difference between geriatric HCC patients and younger HCC controls in the overall survival in the subpopulation of patients with no known comorbidities (p = 0.5), one and two comorbidities (p = 0.49), and three or more comorbidities (p = 0.39). Log (CRP), log (NLR), log (PLR), and log (SII) were all associated with the three-year survival in geriatric HCC patients in simple logistic regression analyses. However, this time, only log (NLR) remained associated even after controlling for the age and BCLC confounding (OR 5.32, 95% CI 1.43–28.85). Conclusions. We found no differences in overall survival and progression-free survival between older and younger HCC patients. Parameters of subclinical inflammation predict prognosis in geriatric patients with HCC. A limitation of the study is small number of the treated patients; therefore, further investigation is warranted. |
format | Online Article Text |
id | pubmed-9318669 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-93186692022-07-27 Inflammatory Indexes as Prognostic Factors of Survival in Geriatric Patients with Hepatocellular Carcinoma: A Case Control Study of Eight Slovak Centers Safcak, Dominik Drazilova, Sylvia Gazda, Jakub Andrasina, Igor Adamcova-Selcanova, Svetlana Balazova, Lea Barila, Radovan Mego, Michal Rac, Marek Skladany, Lubomir Zigrai, Miroslav Janicko, Martin Jarcuska, Peter J Clin Med Article Background and Aims: Hepatocellular cancer (HCC) often occurs in geriatric patients. The aim of our study was to compare overall survival and progression-free survival between geriatric patients (>75 years) and patients younger than 75 years and to identify predictive factors of survival in geriatric patients with HCC. Material and Methods: We performed a retrospective analysis of patients with HCC diagnosed in Slovakia between 2010–2016. Cases (HCC patients ≥75 years) were matched to controls (HCC patients <74 years) based on the propensity score (gender, BCLC stage and the first-line treatment). Results: We included 148 patients (84 men, 57%) with HCC. There were no differences between cases and controls in the baseline characteristics. The overall survival in geriatric patients with HCC was comparable to younger controls (p = 0.42). The one-, two-, and three-year overall survival was 42% and 31%, 19% and 12%, and 12% and 9% in geriatric patients and controls, respectively (p = 0.2, 0.4, 0.8). Similarly, there was no difference in the one- and two-year progression-free survival: 28% and 18% vs. 10% and 7% in geriatric HCC patients and controls, respectively (p = 0.2, 1, -). There was no case–control difference between geriatric HCC patients and younger HCC controls in the overall survival in the subpopulation of patients with no known comorbidities (p = 0.5), one and two comorbidities (p = 0.49), and three or more comorbidities (p = 0.39). Log (CRP), log (NLR), log (PLR), and log (SII) were all associated with the three-year survival in geriatric HCC patients in simple logistic regression analyses. However, this time, only log (NLR) remained associated even after controlling for the age and BCLC confounding (OR 5.32, 95% CI 1.43–28.85). Conclusions. We found no differences in overall survival and progression-free survival between older and younger HCC patients. Parameters of subclinical inflammation predict prognosis in geriatric patients with HCC. A limitation of the study is small number of the treated patients; therefore, further investigation is warranted. MDPI 2022-07-19 /pmc/articles/PMC9318669/ /pubmed/35887947 http://dx.doi.org/10.3390/jcm11144183 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Safcak, Dominik Drazilova, Sylvia Gazda, Jakub Andrasina, Igor Adamcova-Selcanova, Svetlana Balazova, Lea Barila, Radovan Mego, Michal Rac, Marek Skladany, Lubomir Zigrai, Miroslav Janicko, Martin Jarcuska, Peter Inflammatory Indexes as Prognostic Factors of Survival in Geriatric Patients with Hepatocellular Carcinoma: A Case Control Study of Eight Slovak Centers |
title | Inflammatory Indexes as Prognostic Factors of Survival in Geriatric Patients with Hepatocellular Carcinoma: A Case Control Study of Eight Slovak Centers |
title_full | Inflammatory Indexes as Prognostic Factors of Survival in Geriatric Patients with Hepatocellular Carcinoma: A Case Control Study of Eight Slovak Centers |
title_fullStr | Inflammatory Indexes as Prognostic Factors of Survival in Geriatric Patients with Hepatocellular Carcinoma: A Case Control Study of Eight Slovak Centers |
title_full_unstemmed | Inflammatory Indexes as Prognostic Factors of Survival in Geriatric Patients with Hepatocellular Carcinoma: A Case Control Study of Eight Slovak Centers |
title_short | Inflammatory Indexes as Prognostic Factors of Survival in Geriatric Patients with Hepatocellular Carcinoma: A Case Control Study of Eight Slovak Centers |
title_sort | inflammatory indexes as prognostic factors of survival in geriatric patients with hepatocellular carcinoma: a case control study of eight slovak centers |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9318669/ https://www.ncbi.nlm.nih.gov/pubmed/35887947 http://dx.doi.org/10.3390/jcm11144183 |
work_keys_str_mv | AT safcakdominik inflammatoryindexesasprognosticfactorsofsurvivalingeriatricpatientswithhepatocellularcarcinomaacasecontrolstudyofeightslovakcenters AT drazilovasylvia inflammatoryindexesasprognosticfactorsofsurvivalingeriatricpatientswithhepatocellularcarcinomaacasecontrolstudyofeightslovakcenters AT gazdajakub inflammatoryindexesasprognosticfactorsofsurvivalingeriatricpatientswithhepatocellularcarcinomaacasecontrolstudyofeightslovakcenters AT andrasinaigor inflammatoryindexesasprognosticfactorsofsurvivalingeriatricpatientswithhepatocellularcarcinomaacasecontrolstudyofeightslovakcenters AT adamcovaselcanovasvetlana inflammatoryindexesasprognosticfactorsofsurvivalingeriatricpatientswithhepatocellularcarcinomaacasecontrolstudyofeightslovakcenters AT balazovalea inflammatoryindexesasprognosticfactorsofsurvivalingeriatricpatientswithhepatocellularcarcinomaacasecontrolstudyofeightslovakcenters AT barilaradovan inflammatoryindexesasprognosticfactorsofsurvivalingeriatricpatientswithhepatocellularcarcinomaacasecontrolstudyofeightslovakcenters AT megomichal inflammatoryindexesasprognosticfactorsofsurvivalingeriatricpatientswithhepatocellularcarcinomaacasecontrolstudyofeightslovakcenters AT racmarek inflammatoryindexesasprognosticfactorsofsurvivalingeriatricpatientswithhepatocellularcarcinomaacasecontrolstudyofeightslovakcenters AT skladanylubomir inflammatoryindexesasprognosticfactorsofsurvivalingeriatricpatientswithhepatocellularcarcinomaacasecontrolstudyofeightslovakcenters AT zigraimiroslav inflammatoryindexesasprognosticfactorsofsurvivalingeriatricpatientswithhepatocellularcarcinomaacasecontrolstudyofeightslovakcenters AT janickomartin inflammatoryindexesasprognosticfactorsofsurvivalingeriatricpatientswithhepatocellularcarcinomaacasecontrolstudyofeightslovakcenters AT jarcuskapeter inflammatoryindexesasprognosticfactorsofsurvivalingeriatricpatientswithhepatocellularcarcinomaacasecontrolstudyofeightslovakcenters |